Evidence map›Paper›PMID 36005556›Full record

Trial reportHaematologica2022

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.

Walter Fiedler, Pau Montesinos, Christoph Schliemann, Jan Middeke, Sumithira Vasu, Christian W Scholz, Jordi Esteve, Shoubhik Mondal, Björn Rüter, Ute Burkard and 2 more

Open access · goldAbstract readClinical Trial, Phase IIClinical Trial, Phase ILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 4 countries.

Walter FiedlerDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg.
Pau MontesinosHospital Universitari i Politecnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid.
Christoph SchliemannDepartment of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster.
Jan MiddekeUniklinikum Dresden, Dresden.
Sumithira VasuDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Christian W ScholzDepartment of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin.
Jordi EsteveHematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona.
Shoubhik MondalBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
Björn RüterBoehringeaBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Rissr Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
Ute BurkardBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
Annika OsswaldBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss.
William BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. william.g.blum@emory.edu.
Boehringer Ingelheim (India) · INBoehringer Ingelheim (Germany) · DEBoehringer Ingelheim (United States) · USCentro de Investigación Biomédica en Red de Cáncer · ESEmory University · USHospital Clínic de Barcelona · ESKlinik und Poliklinik für Psychotherapie und Psychosomatik · DEThe Ohio State University · USUniversität Hamburg · DEUniversity Hospital Münster · DEVivantes Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteAntibodies, Monoclonal, HumanizedDecitabineHumansImmunoglobulin Fc FragmentsMaximum Tolerated DoseSialic Acid Binding Ig-like Lectin 3Antibodies, Monoclonal, HumanizedBI 836858DecitabineImmunoglobulin Fc FragmentsSialic Acid Binding Ig-like Lectin 3

Identifiers

PMID36005556
PMCPMC9713566
OpenAlexW4292966246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.